Pfizer Initiates Rolling Submission For A New Drug Application In The U.S.

Pfizer Inc. PFE announced today that it has initiated the rolling submission of a New Drug Application to the U.S. Food and Drug Administration for crizotinib, an oral first-in-class anaplastic lymphoma kinase inhibitor for the treatment of patients with advanced non-small cell lung cancer whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.